Answers are grounded in this paper and cite their sources.
Sulbactam–durlobactam in combination with a carbapenem is recommended as the preferred treatment for invasive carbapenem-resistant Acinetobacter baumannii (CRAB) infections in the 2026 Infectious Diseases Society of America guidance. However, clinical experience with sulbactam–durlobactam for treating CRAB-induced central nervous system (CNS) infections remains extremely limited, and intraventricular/intrathecal polymyxins are still recommended as established therapy for CRAB ventriculitis/meningitis. We report two cases of CRAB-induced CNS meningitis/ventriculitis that occurred following cranial neurosurgery. Both patients presented with recurrent fever and altered mental status after brain surgery and showed an inadequate response to conventional antimicrobial regimens, including intravenous polymyxin B with intrathecal or intraventricular administration. After conversion to combination therapy of sulbactam–durlobactam and meropenem, along with neurosurgical intervention, both patients achieved fever control and sustained microbiological and laboratory improvement. These cases provide additional clinical evidence suggesting that, in patients with surgically disrupted blood–brain barriers, intravenous administration of sulbactam–durlobactam in combination with meropenem may represent an effective therapeutic option for CNS infections caused by CRAB. However, the applicability of this regimen may be limited to patients with blood–brain barrier impairment. Its use in this population still requires further pharmacokinetic validation.
No takes yet. Share an insight, caveat, or question.
Chang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: